Editorial: FDA restrictions threaten legacy drugs

The FDA in June began to mandate that unapproved legacy drugs, such as quinine, must undergo the same approval process that new drugs go through as part of the agency's new strategy to improve drug safety. These types of longstanding drugs could be withdrawn for the market unless they submit to the FDA's expensive new drug application process, leading The Wall Street Journal to call for the FDA to give them a "special regulatory pathway" for approval.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide